Gemcitabine Alternatives Compared
Gemcitabine | Opdivo (nivolumab) | Enhertu (fam-trastuzumab deruxtecan) |
|
---|
Gemcitabine | Opdivo (nivolumab) | Enhertu (fam-trastuzumab deruxtecan) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Pancreatic Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer - Metastatic, Breast Cancer, Nasopharyngeal Carcinoma. Gemcitabine may also be used for purposes not listed... View more |
Prescription only
Opdivo is an immune checkpoint inhibitor that may be used to treat many different cancers including melanoma, bladder cancer, liver cancer, colorectal cancer, and lung cancer. Fatigue, skin... View more |
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer, Non Small Cell Lung Cancer, Solid Tumors, Gastric Cancer. Enhertu may also be used for purposes not listed in this medication guide. |
||||||||||||||||||||||||
More about Gemcitabine | More about Opdivo (nivolumab) | More about Enhertu (fam-trastuzumab deruxtecan) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Gemcitabine has an average rating of 8.4 out of 10 from a total of 9 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 0% reported a negative effect. |
Opdivo has an average rating of 5.8 out of 10 from a total of 94 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 40% reported a negative effect. |
Enhertu has an average rating of 8.0 out of 10 from a total of 32 ratings on Drugs.com. 72% of reviewers reported a positive effect, while 3% reported a negative effect. |
||||||||||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Gemcitabine side effects |
View all Opdivo side effects |
View all Enhertu side effects |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
N/A |
N/A |
||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Gemcitabine prices |
View all Opdivo prices |
View all Enhertu prices |
||||||||||||||||||||||||
Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Gemzar, Infugem |
N/A |
N/A |
||||||||||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
10.5 hours |
640.8 hours |
136.8 hours |
||||||||||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 283 drugs are known to interact with Gemcitabine:
|
A total of 589 drugs are known to interact with Opdivo:
|
A total of 175 drugs are known to interact with Enhertu:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
May 15, 1996 |
December 22, 2014 |
N/A |
||||||||||||||||||||||||
WADA Class View classifications | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient Resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Loqtorzi
Loqtorzi (toripalimab-tpzi) is a PD-1 inhibitor medicine used for the treatment of advanced ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.